

# Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

| Medicines                            | WHO Guidelines (DS-TB '17) | WHO Guidelines (Children & Adolescent '22) | EMLc submitted | EMLc (2023) | WHO PQ EOI (2024) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (July 2024) | Global Fund ERP recommended | GDF Catalog | Status                   |
|--------------------------------------|----------------------------|--|----------------|-------------|-------------------|-----------------------------|---------------|---|---------------------------------|-----------------------------|-------------|--------------------------|
| Ethambutol 50mg dispersible tablet   | Yes                        | Yes  | No             | No          | N/A               | N/A                         | Yes           | Yes   | N/A                             | Ineligible for inclusion    | No          | No                       |
| Ethambutol 100mg dispersible tablet  | Yes                        | Yes  | Yes            | Yes         | Yes               | Yes                         | Yes           | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Ineligible for inclusion |
| Ethambutol 100mg tablet              | Yes                        | Yes  | Yes            | Yes         | N/A               | Ineligible for inclusion    | Yes           | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Ineligible for inclusion |
| Ethionamide 125mg dispersible tablet | N/A                        | Yes  | Yes            | Yes         | Yes               | N/A                         | Yes           | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Ineligible for inclusion |
| Isoniazid 50mg dispersible tablet    | Yes                        | Yes  | No             | No          | N/A               | Ineligible for inclusion    | Yes           | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | No          | No                       |
| Isoniazid 100mg dispersible tablet   | Yes                        | Yes  | Yes            | Yes         | Yes               | Yes                         | Yes           | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Ineligible for inclusion |
| Isoniazid 100mg tablet               | Yes                        | Yes  | Yes            | Yes         | N/A               | Ineligible for inclusion    | Yes           | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Ineligible for inclusion |

DS-TB: Drug-Susceptible TB  
 EML: Essential Medicines List  
 EOI: Expression of Interest  
 ERP: Expert Review Panel  
 SRA: Stringent Regulatory Authority  
 WHO PQ: World Health Organization Prequalification of Medicines Programme  
 Version: November 2024

# Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

| Medicines  | WHO Guidelines (DS-TB '17) | WHO Guidelines (Children & Adolescent '22) | EMLc submitted | EMLc (2023) | WHO PQ EOI (2024) | WHO PQ Dossier Under Review | WHO PQ listed            | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (July 2024) | Global Fund ERP recommended | GDF Catalog | Status |
|--|----------------------------|--|----------------|-------------|-------------------|-----------------------------|--------------------------|---|---------------------------------|-----------------------------|-------------|--------|
| Isoniazid 300mg tablet/capsule                                   | Yes                        | Yes  | Yes            | Yes         | Yes               | Yes                         | Yes                      | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Yes    |
| Pyrazinamide 150mg dispersible tablet                            | Yes                        | Yes  | Yes            | Yes         | Yes               | N/A                         | Yes                      | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Yes    |
| Rifampicin 20mg/mL oral liquid                                   | Yes                        | Yes  | Yes            | Yes         | No                | Ineligible for inclusion    | Ineligible for inclusion | No  | No                              | Ineligible for inclusion    | No          | No     |
| Rifampicin/Isoniazid 75/50 dispersible tablet                    | Yes                        | Yes  | Yes            | Yes         | Yes               | N/A                         | Yes                      | Yes   | Ineligible for inclusion        | Ineligible for inclusion    | Yes         | Yes    |
| Rifampicin/Isoniazid/Pyrazinamide 75/50/150mg dispersible tablet | Yes                        | Yes  | Yes            | Yes         | Yes               | Yes                         | Yes                      | Yes   | Yes                             | Yes                         | Yes         | Yes    |

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024